Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 20;13(1):16. doi: 10.1038/s41419-021-04461-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Correlation analysis between E-cadherin/N-cadherin protein expression and LRG1 expression in CRC primary tumors in CPTAC database. b Graph showing LRG1 protein expression in CRC primary tumor with two different integrated phenotypes (epithelial versus EMT) based on data from CPTAC. c EMT associated markers were analyzed by qRT-PCR in DLD-1 and HCT-116 upon treatment with control medium or CM from two individual CAF. d EMT associated markers and phosphorylated Smad1/5(ser463/465) were analyzed by western blot in DLD-1 and HCT-116 upon treatment with control medium or CM from two individual CAF. e DLD-1 and HCT-116 with or without silencing of LRG1 were treated with control medium or CM from CAF. Expression of EMT-associated markers was measured by qRT-PCR. f DLD-1 and HCT-116 with or without silencing of LRG1 were treated with control medium or CM from CAF. Expression of EMT-associated markers and phosphorylated Smad1/5(ser463/465) was measured by western blot. g Expression of EMT-associated markers was measured by qRT-PCR in DLD-1 and HCT-116 with or without ectopic expression of LRG1. h Expression of EMT-associated markers and phosphorylated Smad1/5(ser463/465) was measured by western blot in DLD-1 and HCT-116 with or without ectopic expression of LRG1. i DLD1 and HCT-116 in the presence or absence of LRG-1 overexpression were pre-treated with SB431542, a TGFβ-Smad pathway inhibitor, or not. Expression of LRG1, phosphorylated Smad1/5 (ser463/465) and EMT-associated markers were measured by western blot. Error bars represent SD; n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.